224 related articles for article (PubMed ID: 29125591)
21. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
Teraki Y; Takahashi A; Inoue Y; Takamura S
Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
[No Abstract] [Full Text] [Related]
22. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
Nast A; Spuls PI; van der Kraaij G; Gisondi P; Paul C; Ormerod AD; Saiag P; Smith CH; Dauden E; de Jong EM; Feist E; Jobling R; Maccarone M; Mrowietz U; Papp KA; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Dressler C
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1951-1963. PubMed ID: 28895202
[No Abstract] [Full Text] [Related]
23. [Body-weight changes in psoriatic patients on systemic treatment].
Forien M; Mahé E; Sin C; Marchal A; Sigal ML
Ann Dermatol Venereol; 2012 Oct; 139(10):649-51. PubMed ID: 23122380
[No Abstract] [Full Text] [Related]
24. Effects of risankizumab in patients with psoriasis previously treated with guselkumab: a case series.
Lin PH; Tsai TF
Eur J Dermatol; 2021 Apr; 31(2):251-252. PubMed ID: 33875411
[No Abstract] [Full Text] [Related]
25. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
26. [Up-date on the use of infliximab in dermatology. Introduction].
Sánchez-Carazo J
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
[No Abstract] [Full Text] [Related]
27. Multiple eruptive dermatofibromas in a patient receiving efalizumab.
Santos-Juanes J; Coto-Segura P; Mallo S; Galache C; Soto J
Dermatology; 2008; 216(4):363. PubMed ID: 18292655
[No Abstract] [Full Text] [Related]
28. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
[No Abstract] [Full Text] [Related]
29. Advances in psoriasis treatment.
Schön MP
Lancet; 2005 Oct 15-21; 366(9494):1333-5. PubMed ID: 16226595
[No Abstract] [Full Text] [Related]
30. Secukinumab for psoriasis in a patient with hepatitis B.
Feaster B; Cline A; Feldman SR
Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677838
[TBL] [Abstract][Full Text] [Related]
31. Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors.
Oiwa T; Honda T; Otsuka A; Kabashima K
J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):e122-e123. PubMed ID: 28983980
[No Abstract] [Full Text] [Related]
32. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.
Schmidt C
Nat Biotechnol; 2015 Sep; 33(9):894-5. PubMed ID: 26348946
[No Abstract] [Full Text] [Related]
33. Tremfya™ (Guselkumab).
Abramovits W; Wiqas A; Vincent KD; Versteeg SG; Gupta AK
Skinmed; 2019; 17(1):36-38. PubMed ID: 30888946
[No Abstract] [Full Text] [Related]
34. [Final recommendations to incorporate efalizumab into the clinical practice].
García-Díez A; Ferrándiz C
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():82. PubMed ID: 18341857
[No Abstract] [Full Text] [Related]
35. Coexistent psoriasis and lupus erythematosus treated with alefacept.
Berthelot C; Nash J; Duvic M
Am J Clin Dermatol; 2007; 8(1):47-50. PubMed ID: 17298107
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapy for psoriasis.
Lee M; Kalb RE
Dermatol Nurs; 2008 Apr; 20(2):105-11; quiz 112. PubMed ID: 18549125
[TBL] [Abstract][Full Text] [Related]
37. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
Dressler C; Rosumeck S; Werner RN; van der Kraaij G; van Lumig P; Wakkee M; Spuls P; Nast A
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1964-1977. PubMed ID: 28944515
[No Abstract] [Full Text] [Related]
38. Alopecia areata during treatment with biologic agents.
Tosti A; Pazzaglia M; Starace M; Bellavista S; Vincenzi C; Tonelli G
Arch Dermatol; 2006 Dec; 142(12):1653-4. PubMed ID: 17179002
[No Abstract] [Full Text] [Related]
39. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
[TBL] [Abstract][Full Text] [Related]
40. Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression.
Yip L; Harrison S; Foley P
Australas J Dermatol; 2008 Nov; 49(4):250-1. PubMed ID: 18855796
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
